Science News

... from universities, journals, and other research organizations

Patients Are Living Longer With ICDs, but Pacing Impacts Survival Rates

Aug. 28, 2011 — The adverse effect of right ventricular pacing on implantable cardioverter-defibrillator (ICD) patient survival is sustained long-term; however, the impact appears to be mitigated by cardiac resynchronization therapy (CRT), based on a scientific poster being presented at the European society of Cardiology (ESC) Congress Aug 28 in Paris.


Share This:

"We were pleased to discover that the average patient, despite having severe left ventricular dysfunction, lived nine years after ICD implantation, which are the best results that we are aware of," according to lead author Robert G. Hauser, MD, cardiac electrophysiologist at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis.

The researchers followed all 1,395 ICD patients at Minneapolis Heart Institute® who were 18 years or older with ejection fraction 35 percent or greater between 2000 and 2009. Of these patients, 673 had ICD-CRT and were paced in both lower chambers of the heart; 468 patients had single or dual chamber ICDs and most were paced in the right ventricle less than 10 percent of the time; and 59 had single or dual chamber ICDs and were paced in the right ventricle continuously.

The study had two objectives: the predictors of survival in this population and the effect of right ventricular pacing on survival.

Importantly, the researchers found that survival of CRT patients was similar to single and dual chamber ICD patients paced less than 10 percent of the time. Patients who were paced continuously in the right ventricle did not live as long as either the CRT patients or the patients who were infrequently paced in the right ventricle. "Thus, pacing had an adverse effect on survival," Hauser said. "We also found that if the right and the left side of the heart were paced in synchrony, the patients fared better."

Other factors associated with improved survival were treatment with an ACE inhibitor or an ARB; the age of the patient, meaning those who were younger lived longer; and if the patients did not have certain underlying diseases, including heart failure, chronic kidney disease, and peripheral arterial disease.

Based on their findings, Hauser made these recommendations: "If a patient has to be paced because of a slow heart rate, their outcomes will be better if both chambers of the heart are paced, rather than just the right side. Further, every effort should be made to treat these patients with an ACE inhibitor or an ARB."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

|

Story Source:

The above story is reprinted from materials provided by Minneapolis Heart Institute Foundation, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


APA

MLA

Note: If no author is given, the source is cited instead.

Search ScienceDaily

Number of stories in archives: 137,088

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

Recommend ScienceDaily on Facebook, Twitter, and Google:

Other social bookmarking and sharing services:

|

 
  more breaking science news

Social Networks


Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

|

Breaking News

... from NewsDaily.com

In Other News ...

Science Video News


Heated Chemo

In efforts to boost the effectiveness of anti-cancer drugs, a new method called intra-peritoneal hyperthermic chemotherapy works by flushing a heated. ...  > full story

Strange Science News

 

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

Post this page to your favorite social bookmarking site:
Include this item in your blog or web site:
Cite this article in your essay, paper, or report:
Email this page's link to a friend or colleague: